NewNew DrugsDrugs fromfrom MarineMarine BacteriaBacteria
Sergey B. Zotchev, NTNU/Biosergen AS August 7, 2009 OutlineOutline
• Bioprospecting for new drugs in the Trondheim fjord
• Biosynthetic engineering at Biosergen AS Bioprospecting for antibiotics: what’s important?
• Where to look – search for unique ecological niches;
• How to look – establishment of cultivation techniques;
• How to reveal the potential – choice of production media and conditions;
• How to assess activity – assay development;
• How to assess novelty – development of analytical techniques;
• How to reveal mechanism of action – use of molecular biology;
• How to evaluate usefulness – in vitro and in vivo studies. Trondheim fjord Sampling sponges in the Trondheim fjord
Total: 960 isolates Actinobacteria from sponges TSI 123-18 TSI 128-18 TSI 124-18
63 TSI 129-2 TSI 118-17 TSI 122-5 100 TSI 125-23 Micromonospora matsumotoense IMSNU 22... 48 TSI 125-1
53 TSI 115-7 TSI 121-5 Micromonospora 37 82 TSI 117-18 TSI 117-17 52
46 Micromonospora sp. lupac 09 77 45 TSI 117-5 Micromonospora carbonacea DSM 43815 100 TSI 114-4 Micromonospora auratinigra TT1-11
91 TSI 121-19 51 98 TSI 129-13
66 Pseudonocardia petroleophila IMSNU 22... 100 TSI 115-15 Pseudonocardia TSI 116-13
100 Rhodococcus opacus B-4 68 TSI 124-19 Rhodococcus
41 Actinoalloteichus spitiensis MTCC 6194 TSI 127-17 100 TSI 115-14 Actinoalloteichus 100 Actinoalloteichus 87 TSI 129-23
64 TSI 116-3 15 65 TSI 124-17 16 Streptosporangium sp. 14363 27 TSI 129-5 90 TSI 124-2
100 Streptosporangium TSI 115-20 Streptosporangium amethystogenes DSM ... 100 98 TSI 129-12 Sponges: Nonomuraea kuesteri GW 14-1925T 99 Nonomuraea 99 Nonomuraea TSI 116-8 Nocardiopsis sp. YIM 80031 100 TSI 112-9 Nocardiopsis 100 TSI 112-24 Geodia barretti 34 59 TSI 119-9 98 Streptomyces ramulosus NRRL B-2714 TSI 113-5 Streptomyces Isops phlegraei 100 TSI 120-18 100 TSI 117-4 Streptomycetaceae bacterium CNR530 Mycale lingua 73 100 TSI 112-12 86 TSI 116-4 39 30 TSI 113-17 Phakellia ventilabrum Streptomyces sp. Fiji-204 Streptomyces (marine) 61 TSI 115-17 TSI 112-13 52 Antho dichotoma TSI 112-10 Antho dichotoma 100
53 TSI 112-23 92 TSI 115-22
99 TSI 105-24 Isoptericola sp. TUT1258 Isoptericola Depth: 60-121 m 100 Promicromonospora sp. YIM C653 TSI 106-17 100 TSI 98-01 98 Promicromonospora 76 TSI 105-21 Bifidobacterium bifidum DSM 20456T
0.02 Compounds identified: some examples
Biological Producing organism Chemical class Identification activity
Anti-bacterial, Streptomyces sp. Polypeptide Actinomycin D cytotoxic
Streptomyces sp. Polyene macrolide Anti-fungal Candicidin D
Streptomyces sp. Polyketide-pyrrole Anti-bacterial Pyrrolomycins
Streptomyces sp. Macrolactam Cytotoxic BE-14106
Streptomyces sp. Cyclodepsipeptide Anti-bacterial Valinomycin
Streptosporangium sp. Phenazine Cytotoxic Iodinin
Streptomyces sp. Polyketide Anti-bacterial New
Streptomyces sp. Polyene macrolide Anti-fungal New
Streptomyces sp. Macrolactam Cytotoxic New
Nocardiopsis sp. Thiopeptide Anti-bacterial New
Actinoalloteichus sp. ? Anti-bacterial New
Actinomadura sp. ? Anti-bacterial New Structures of the new molecules from marine bacteria
O N OH HO
TP-1161 ML-449
Antibacterial Cytotoxic thiopeptide macrolactam Hidden genome treasures
Geodia barretti
Anti-bacterial activity Actinoalloteichus sp. (halogenated polyketide)
Genome sequencing
Nocardicin (monocyclic β-lactam, anti-bacterial) Halogenated polyketide 1 (anti-bacterial) Halogenated polyketide 2 (anti-bacterial?) Aromatic poyketide 1 (anti-cancer?) Aromatic polyketide 2 (anti-cancer/anti-bacterial?) Glycosylated macrolide (anti-bacterial?) Glycosylated aromatic polyketide (anti-cancer?) Polyene macrolide (anti-fungal) Enediyne (anti-cancer) Lantibiotic (anti-bacterial) Isoprenoid (?) Hybrid polyketide/peptide (?) WhatWhat dodo wewe havehave soso far?far?
•> 10.000 actinomycete isolates (neuston layer, sediments and sponges)
• Technology established: from cultivation to identification/isolation of active compounds
• Identified >100 anti-bacterial and >30 anti-fungal ”hits” (currently under characterization)
• 29 anti-cancer ”hits” (currently under characterization)
• Identified at least 6 new antibiotics – 4 anti-bacterial, 1 anti-fungal, 1 cytotoxic
• New opportunities for drug discovery through draft genome sequencing
• Unique antibiotic biosynthesis gene clusters identifed/cloned Nystatin: an anti-fungal polyene macrolide
Streptomyces noursei
OH OH H3C O OH
HO O OH OH OH OH O CH3 COOH
CH3 CH O O 3 Elizabeth Hazen & Rachel F. Brown Nystatin A1 OH OH NH2
Toxic. Used for treatment of superficial fungal infections only Nystatin biosynthesis in Streptomyces noursei
Fjærvik & Zotchev, 2005 Engineered biosynthesis of a heptaene nystatin analogue
Module 5 Module 5
ER ER DH KR DH KR
OH OH OH OH H3C O OH H3C O OH
HO O OH OH OH OH O HO O OH OH OH OH O CH3 COOH CH3 COOH 29 29
CH3 28 CH3 28 CH CH O O 3 O O 3 Nystatin OH S44HP OH
OH NH2 OH NH2
MIC50 =0.45µg/ml MIC50 = 0.075 µg/ml
Activity increased ca 6-fold
Bruheim et al., 2004 • Established – December 2004
• Shareholders – SINTEF Venture AS (Norway), Verdane Capital AS (Norway), Karolinska Development AB (Sweden), OBS Østersjøstiftelsen (Sweden)
• Mission – development of a safer and more efficient drug against systemic fungal infections
• Technology – manipulation of the nystatin biosynthetic genes + optional chemical modifications
• Partners – SINTEF, NTNU, Gause Institute of New Antibiotics (Russia), Biovian (Finland), Visionar (Sweden) HowHow dodo wewe makemake newnew nystatinnystatin analogues?analogues?
• Molecular design according to current knowledge on structure-activity relationship;
• Genetic design in accordance with nystatin biosynthetic pathway;
• Genetic manipulation of the bacterium, verification of the mutation;
• Fermentation of the genetically manipulated bacterium, identification of desired product, and its purification;
• Chemical modifications of genetically engineered analogues. Engineered antibiotic analogues
OH OH H3C O OH
HO O OH OH OH OH O CH3 COOH 29
CH3 28 CH O O 3 S44HP OH
OH NH2
Genetics Chemistry 15 analogues 49 analogues & salts
in vitro & in vivo evaluation, analysis of SAR data
6 pre-CD candidates
Pre-CD study package
Candidate drug Now here Bioprospecting + Biosergen AS?
• Large collection of actinobacteria, many belonging to rare species
• Large pool of unique antibiotic biosynthesis genes: at least 15 gene clusters for biosynthesis of potentially novel antibiotics identified through genome sequencing
• Two novel gene clusters for biosynthesis of cytotoxic antibiotics cloned, sequenced and annotated (one forms a basis for a new anti-cancer project at Biosergen)
• Possibility to expand project portfolio: biosynthetic engineering of new anti-cancer and anti-bacterial antibiotics AcknowledgementsAcknowledgements
• NTNU: S.E.F. Borgos, A. Nedal, E. Fjærvik, P. Bruheim, H. Bredholt, G. Johnsen, H. Jørgensen, S. Hakvåg, K. Engelhardt, E. Ian, S. Valla, A.R. Strøm
• SINTEF: H. Sletta, T. Brautaset, G. Klinkenberg, K. Degnes, K. Josefsen, K. Zahlsen, R. Aune, T.E. Ellingsen
• Biosergen AS: I. Bakke, O. Sekurova, O. Volokhan
• University of Bergen: L. Herfindal, H.T. Rapp, S.O. Døskeland
• Gause Institute (Russia):(Russia) L. Terekhova, E. Olsufyeva, M. Preobrazhenskaya
• ChemDiv, Inc. (USA/Russia):(USA/Russia) D. Tyrsin, V. Kazey
• Biofocus DPI (Switzerland):(Switzerland) M. Kemmler
Financial support: Research Council of Norway, Sinvent AS, Biosergen AS, NTNU, UiB